The use of oral antifungal agents to treat onychomycosis (Q35211943)

7 August 2017

1 reference

title

The use of oral antifungal agents to treat onychomycosis (English)

1 reference

7 August 2017

Aditya K Gupta

1

0 references

author name string

Jennifer E Ryder

series ordinal

2

1 reference

7 August 2017

1 July 2003

1 reference

7 August 2017

1 reference

7 August 2017

21

1 reference

7 August 2017

3

1 reference

7 August 2017

469-79, vi

1 reference

Pharmacokinetics of antifungal agents in onychomycoses

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Kinetics and spectrum of activity of oral antifungals: the therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Pharmacokinetic optimisation of oral antifungal therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Onychomycosis: a compendium of facts and a clinical experience

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Pharmacokinetics of three doses of once-weekly fluconazole (150, 300, and 450 mg) in distal subungual onychomycosis of the toenail

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Clinical pharmacokinetics of fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the toenail

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Once-weekly fluconazole (450 mg) for 4, 6, or 9 months of treatment for distal subungual onychomycosis of the toenail

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Fluconazole for the treatment of onychomycosis: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Itraconazole: an effective oral antifungal for onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Optimisation of itraconazole therapy using target drug concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Itraconazole for the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Influence of an acidic beverage (Coca-Cola) on the absorption of itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

The clinical pharmacokinetics of itraconazole: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Pharmacokinetics and pharmacology of terbinafine and itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Pharmacokinetic profile of orally administered itraconazole in human skin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Itraconazole penetrates the nail via the nail matrix and the nail bed--an investigation in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Antifungal agents: an overview. Part II.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Terbinafine: mode of action and properties of the squalene epoxidase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Terbinafine, a unique oral antifungal: current perceptions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

The mechanism of action of terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Nail incorporation kinetics of terbinafine in onychomycosis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Levels of terbinafine in plasma, stratum corneum, dermis-epidermis (without stratum corneum), sebum, hair and nails during and after 250 mg terbinafine orally once daily for 7 and 14 days

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Pharmacokinetics of terbinafine in the nail

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Long-term results in patients with onychomycosis treated with terbinafine or itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Long-term efficacy of antifungals in toenail onychomycosis: a critical review

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Oral treatments for toenail onychomycosis: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Long-term outcomes in the treatment of toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Safety of oral terbinafine for toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Effect of fluconazole on the disposition of phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Effects of fluconazole and clarithromycin on rifabutin and 25-O-desacetylrifabutin pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Rifampin-fluconazole interaction in critically ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Itraconazole and hydroxyitraconazole serum concentrations are reduced more than tenfold by phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Effect of itraconazole on the pharmacokinetics of atorvastatin

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Interaction between terbinafine and warfarin.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Terbinafine and potential drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Serious interaction between warfarin and oral terbinafine

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

Investigation of terbinafine as a CYP2D6 inhibitor in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0733-8635%2803%2900027-5

7 January 2021

10.1016/S0733-8635(03)00027-5

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

12956199